|
1
|
Ponticelli C: Membranous nephropathy. J
Nephrol. 20:268–287. 2007.PubMed/NCBI
|
|
2
|
Beck LH Jr, Bonegio RG, Lambeau G, Beck
DM, Powell DW, Cummins TD, Klein JB and Salant DJ: M-type
phospholipase A2 receptor as target antigen in idiopathic
membranous nephropathy. N Engl J Med. 361:11–21. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Qin W, Beck LH Jr, Zeng C, Chen Z, Li S,
Zuo K, Salant DJ and Liu Z.: Anti-phospholipase A2 receptor
antibody in membranous nephropathy. J Am Soc Nephrol. 22:1137–1143.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Hofstra JM, Beck LH Jr, Beck DM, Wetzels
JF and Salant DJ: Anti-phospholipase A2 receptor antibodies
correlate with clinical status in idiopathic membranous
nephropathy. Clin J Am Soc Nephrol. 6:1286–1291. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Prunotto M, Carnevali ML, Candiano G,
Murtas C, Bruschi M, Corradini E, Trivelli A, Magnasco A, Petretto
A, Santucci L, et al: Autoimmunity in membranous nephropathy
targets aldose reductase and SOD2. J Am Soc Nephrol. 21:507–519.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Cattran DC, Feehally J, Cook HT, Liu ZH,
Fervenza FC, Mezzano SA, Floege J, Nachman PH, Gipson DS, Praga M,
et al: Kidney Disease: Improving Global Outcomes (KDIGO)
Glomerulonephritis Work Group. KDIGO clinical practice guideline
for glomerulonephritis. Kidney Int Suppl. 2:186–197. 2012.
|
|
7
|
Polanco N, Gutiérrez E, Covarsí A, Ariza
F, Carreño A, Vigil A, Baltar J, Fernández-Fresnedo G, Martín C,
Pons S, et al: Grupo de Estudio de las Enfermedades Glomerulares de
la Sociedad Española de Nefrología: Spontaneous remission of
nephrotic syndrome in idiopathic membranous nephropathy. J Am Soc
Nephrol. 21:697–704. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Polanco N, Gutiérrez E, Rivera F,
Castellanos I, Baltar J, Lorenzo D and Praga M: Grupo de Estudio de
las Enfermedades Glomerulares de la Sociedad Española de Nefrología
(GLOSEN): Spontaneous remission of nephritic syndrome in membranous
nephropathy with chronic renal impairment. Nephrol Dial Transplant.
27:231–234. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Cattran D: Management of membranous
nephropathy: When and what for treatment. J Am Soc Nephrol.
16:1188–1194. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Glassock RJ: Diagnosis and natural course
of membranous nephropathy. Semin Nephrol. 23:324–332. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Du Y, Li J, He F, Lv Y, Liu W, Wu P, Huang
J, Wei S and Gao H: The diagnosis accuracy of PLA2R-AB in the
diagnosis of idiopathic membranous nephropathy: A meta-analysis.
PLoS One. 9:e1049362014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Bech AP, Hofstra JM, Brenchley PE and
Wetzels JF: Association of anti-PLA2R antibodies with outcomes
after immunosuppressive therapy in idiopathic membranous
nephropathy. Clin J Am Soc Nephrol. 9:1386–1392. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Kanigicherla D, Gummadova J, McKenzie EA,
Roberts SA, Harris S, Nikam M, Poulton K, McWilliam L, Short CD,
Venning M and Brenchley PE: Anti-PLA2R antibodies measured by ELISA
predict long-term outcome in a prevalent population of patients
with idiopathic membranous nephropathy. Kidney Int. 83:940–948.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Segarra-Medrano A, Jatem-Escalante E,
Carnicer-Cáceres C, Agraz-Pamplona I, Salcedo MT, Valtierra N,
Ostos-Roldán E, Arredondo KV and Jaramillo J: Evolution of antibody
titre against the M-type phospholipase A2 receptor and clinical
response in idiopathic membranous nephropathy patients treated with
tacrolimus. Nefrologia. 34:491–497. 2014.(In English, Spanish).
PubMed/NCBI
|
|
15
|
Hofstra JM, Debiec H, Short CD, Pellé T,
Kleta R, Mathieson PW, Ronco P, Brenchley PE and Wetzels JF:
Antiphospholipase A2 receptor antibody titer and subclass in
idiopathic membranous nephropathy. J Am Soc Nephrol. 23:1735–1743.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Ponticelli C and Passerini P: Can
prognostic factors assist therapeutic decisions in idiopathic
membranous nephropathy. J Nephrol. 23:156–163. 2010.PubMed/NCBI
|
|
17
|
Ronco P and Debiec H: Pathophysiological
advances in membranous nephropathy: Time for a shift in patient's
care. Lancet. 385:1983–1992. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Ruggenenti P, Debiec H, Ruggiero B,
Chianca A, Pellé T, Gaspari F, Suardi F, Gagliardini E, Orisio S,
Benigni A, et al: Anti phospholipase A2 receptor antibody titer
predicts post-rituximab outcome of membranous nephropathy. J Am Soc
Nephrol. 26:2545–2558. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Liu H and Luo W: GONG Shaomin Detection
and the clinical significance of phospholipase A2 receptor in
idiopathic membranous nephropathy tissues. Fudan University Journal
of Medical Sciences. 42:2015.
|
